Researchers Built AI Database for 3D Printed Drugs

The University of Mississippi and Colorcon partnered to automate the production of personalized medication.

Updated on Sept. 21, 2026 in Biotech

Bold vector editorial illustration of a robotic precision nozzle depositing polymer, representing pharmaceutical 3D printing automation. — The University of Mississippi and Colorcon have developed an AI-driven database to automate the compounding of personalized 3D-printed medications. AI Illustration. Upload story photo >

Live Poll

Would you prefer to receive personalized, 3D-printed medications from your local pharmacy instead of mass-produced pills?

Researchers at the University of Mississippi have teamed up with Colorcon to create an AI-powered database designed to streamline the production of 3D-printed medications. The tool aims to simplify the process by automatically matching drug ingredients for pharmacists.

Why it matters

Traditional methods for creating personalized medicine are currently impractical to scale, while many pharmacists lack the training to manage 3D printing equipment. This AI initiative seeks to overcome these hurdles, potentially bringing 3D-printed therapies into routine use.

Previous research from FabRx, published in February 2025, demonstrated that automated capsule filling technology can achieve a 55% reduction in manual labor and a 10% reduction in preparation time.

The players

University of Mississippi

This public research institution houses the lab currently developing AI systems for medical 3D printing.

Colorcon

This company specializes in pharmaceutical film coatings and has partnered with researchers to advance medication formulation technologies.

Mo Maniruzzaman

He leads the research laboratory at the University of Mississippi overseeing the AI-driven drug printing project.

CurifyLabs

This biotech firm is a key player in the sector and recently secured substantial capital to advance its automated drug production capabilities.

FabRx

This company is known for its research into 3D printing technology and pharmaceutical manufacturing automation.

The details

The newly developed algorithm functions by identifying and matching compatible active and inactive drug ingredients, sending instructions directly to 3D printers. This automation is intended to lower the technical barrier for medical professionals who manage personalized prescriptions.

February 2025: FabRx published a study regarding automated capsule filling.
July 2026: CurifyLabs secured $14 million in Series A funding.
September 21, 2026: The research partnership was officially reported.

Roadmap

The transition toward 3D-printed medication represents a shift from mass-market manufacturing to highly customized, on-demand drug delivery. By automating the technical parameters of production, this AI initiative directly builds upon the mechanical precedents set by earlier systems like the M3DIMAKER.

For patients, this development may eventually result in more precise medication dosages formulated on-site at pharmacies. It promises to reduce waiting times for customized prescriptions while lowering the likelihood of errors associated with manual ingredient selection.

The takeaway

AI-driven automation is poised to move 3D-printed drugs out of clinical research and into practical daily use at local pharmacies. This shift suggests that in the coming years, complex medication formulations could be generated and dispensed with the efficiency of standard manufacturing.